| Human immunodeficiency virus I infection

Intelence vs Juluca

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.
Deep comparison between: Intelence vs Juluca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsJuluca has a higher rate of injection site reactions vs Intelence based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juluca but not Intelence, including UnitedHealthcare
Sign up to reveal the full AI analysis
Intelence
Juluca
At A Glance
Oral
Twice daily
NNRTI
Oral
Once daily
INSTI/NNRTI combination
Indications
  • Human immunodeficiency virus I infection
  • Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 200 mg (one 200 mg tablet or two 100 mg tablets) orally twice daily following a meal
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Contraindications
—
  • Previous hypersensitivity reaction to dolutegravir or rilpivirine
  • Coadministration with dofetilide
  • Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
  • Coadministration with rifampin or rifapentine
  • Coadministration with systemic dexamethasone (more than a single-dose treatment)
  • Coadministration with St John's wort (Hypericum perforatum)
  • Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=2%) Rash, peripheral neuropathy
Serious Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug hypersensitivity reactions including DRESS, hepatic failure, rhabdomyolysis
Postmarketing Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome, severe hypersensitivity reactions including DRESS and hepatic failure
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Pharmacology
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Intelence
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
Juluca
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Intelence
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
View full coverage details ›
Juluca
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
Humana
Intelence
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Juluca
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
IntelenceView full Intelence profile
JulucaView full Juluca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.